Amarin (AMRN) Stock Price, News & Analysis

Company Overview

Amarin Corporation plc is a biopharmaceutical company focused on developing and commercializing therapies intended to reduce cardiovascular risk. Its principal product is VASCEPA (icosapent ethyl), a prescription omega-3 fatty-acid medicine derived from highly purified eicosapentaenoic acid.

VASCEPA was initially approved in the United States to help lower triglyceride levels in certain patients and later received expanded approval to reduce the risk of cardiovascular events in eligible adults with elevated cardiovascular risk. The product is also marketed in Europe under the name VAZKEPA, where it has been authorized for reducing cardiovascular risk in specified patient populations.

Founded in 1993, Amarin has historically concentrated on the clinical development, regulatory approval, and commercialization of VASCEPA rather than maintaining a broad portfolio of marketed medicines. The company serves patients and healthcare providers primarily in the United States and selected international markets, with its business shaped by cardiovascular research, regulatory activity, commercial partnerships, and competition from generic versions of icosapent ethyl.

Key Stats

• Today's Range: $12.00 to $12.76
• 50-Day Range: $11.32 to $14.39
• 52-Week Range: $11.25 to $17.31
• Volume: 101,276 shs
• Average Volume: 71,366 shs
• Market Capitalization: $254.92 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Hold

Amarin Stock Analysis - MarketRank™

Amarin scored higher than 33% of companies evaluated by MarketBeat, and ranked 757th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Amarin has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, no hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Amarin is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amarin has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Amarin are expected to grow in the coming year, from ($0.85) to ($0.84) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amarin is -12.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amarin is -12.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Amarin has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.63% of the float of Amarin has been sold short.

Short Interest Ratio / Days to Cover

Amarin has a short interest ratio ("days to cover") of 7.28.

Change versus previous month

Short interest in Amarin has recently increased by 0.81%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amarin does not currently pay a dividend.

Dividend Growth

Amarin does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.71

News Sentiment

Amarin has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 16 news articles for Amarin this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for AMRN on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amarin insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.21% of the stock of Amarin is held by insiders.

Percentage Held by Institutions

22.25% of the stock of Amarin is held by institutions.

Company Calendar

• Last Earnings: 10/28/2026
• Today: 10/31/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AMRN
• CIK: 897448
• Web: www.amarincorp.com
• Phone: (531) 669-9020
• Fax: N/A
• Employees: 80
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Amarin: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +7.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$38.80 million
• Net Margins: -10.87%
• Pretax Margin: -9.73%
• Return on Equity: -0.52%
• Return on Assets: -0.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.50
• Quick Ratio: 2.67

Sales & Book Value

• Annual Sales: $213.65 million
• Price / Sales: 1.19
• Cash Flow: $0.36 per share
• Price / Cash Flow: 33.55
• Book Value: $21.04 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 21,120,000
• Free Float: 20,234,000
• Market Cap: $254.92 million
• Optionable: Optionable
• Beta: 0.76